Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk 
CDC Shake-Up Sparks Vaccine Policy Clash Between RFK Jr. and Susan Monarez 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 
Despite conclusive evidence that it’s one of the most dangerous and addictive substances in the world, sugar is still widely used for a variety of purposes. In an effort to curb the effects of this sweet food, substitutes like aspartame have been introduced. Naturally, there were concerns about its supposed effects on health, but a recent study found that there were no causes for concern.
Recently published in The Journal of Nutrition, researchers basically looked into the effects of aspartame on several factors of health. These included glucose tolerance, weight, and appetite. The results indicated that the sugar substitute basically had no negative impact on any of those factors.
“With the exception of the baseline OGTT glucose concentration at 60 min (and resulting area under the curve value), there were no group differences for glucose, insulin, resting leptin, glucagon-like peptide 1, or gastric inhibitory peptide at baseline or week 12,” the results of the study reads. “There also were no effects of aspartame ingestion on appetite, body weight, or body composition.”
The study lasted for 12 weeks from start to finish, and throughout that period, the subjects were divided into three groups. One group took no aspartame while another took 350 mg per day. The third group took a much higher dosage of 1,050 mg of the sugar substitute.
Blood samples were taken from the subjects before the start of the trial and at the end of the 12-week course. Apparently, the participants did not show any significant differences in the factors that the researchers were looking at. In conclusion, the researchers note that their findings do not support the notion that aspartame comes with negative consequences such as obesity and an increase in rates of hunger.
On the other hand, Medical News Bulletin did note that the study received support from Ajinomoto Co., Inc., which produces products such as artificial sweeteners. However, the authors of the study insist that the findings of their aspartame research were not affected by the source of the funds.
